and the part I really liked was "Even if the drug is priced conservatively, Ardelyx appears to be an easy potential multi-bagger of several magnitudes if investors can hold on to it for a decade."

So they are just going to see if they can prescribe their current IBS drug to kids, awesome!

$ARDX IBS drug total rx (TRX)are steady and growing.

$ARDX This company is sitting on a mountain of great fundamentals.. 40++ medical patents ,,, 40+ more in application status 1 drug approved IBSRELA 1 drug almost aproved XPHOZAH a kidney drug that could pull an annual billion dollar + revenue.

$ARDX Most drugs do not peak until 5 years from launch and we are at 1m $ / week after 41 weeks!

Dilution to launch TWO global drugs is money well spent.

They just got approval for 1 drug from FDA and things are bot going well there..

Now we're getting all these new drugs that really work well."

$ARDX come on you this other drug going off and this one is way better what the hell is everybody thinking let’s goooooo

Their drug can save lives, and it is effective even if given less often than competitor ( save IV access, less pain, and save money ).

with reduced susceptibility to FDA-approved echinocandins or provides improved tissue penetration.

It is just because it works - better than any other adhd drug!!!

Not bad vs a 2 billion plus drug.

New treatments and product launches: The development and launch of new and innovative treatments for ADHD, such as extended-release formulations and combination products, is also driving market growth.

$KMPH I dub thee Azstarys a wonder drug.

What a great time to have an up and coming better drug.

Second, Pascoe has a choice of many, many drugs to pluck away for a song. Many!!!

But I see the drug shortage is helping new drugs across the board and Azstarys did better since it is better among all those, imo.

$KMPH we are, qualified, the best ADHD drug on the market; not perfect,

$KMPH Cash position is outstanding, helped by a very efficient burn rate, and pipeline is advancing with 2 drugs that will have significant events in Q3 2023, and sales royalties from Corium will start ramping up in Q1.